Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus

Rocket Pharmaceuticals, Inc. (RCKT) incurred a loss of 71 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 78 cents. In the year-ago quarter, the company had reported a loss of 75 cents per share.In the absence of any marketed product in its portfolio, Rocket Pharmaceuticals did not record any revenues during the third quarter.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.More on RCKT's Q3 ResultsIn the reported quarter, general ...